Controversies in the Treatment of Lung Cancer

1 - Cover [Seite 1]
2 - Contents [Seite 6]
3 - Prognostic Factors in Histopathology ofLung Cancer [Seite 8]
3.1 - Abstract [Seite 8]
3.2 - Tumor Size: An Essential Prognostic Factor in Lung Cancer [Seite 10]
3.3 - Small Cell Lung Cancer [Seite 10]
3.4 - Prognosis and Predictive Factors in Small Cell Lung Cancer [Seite 11]
3.5 - Histological Subtype: A Prognostic Factor in NSCLC [Seite 12]
3.6 - Squamous Cell Carcinoma Histological Subtypes Associated with Poor Prognosis [Seite 12]
3.7 - Adenocarcinoma Histological Subtypes Associated with Poor Prognosis [Seite 13]
3.8 - Bronchioloalveolar Cell Carcinoma Growth Pattern: A Favorable Prognostic Factor [Seite 13]
3.9 - Large Cell Carcinomas [Seite 14]
3.10 - Prognostic Implication of Molecular Markers [Seite 15]
3.11 - Conclusion [Seite 19]
3.12 - References [Seite 20]
4 - FDG-PET/CT in Lung Cancer: An Update [Seite 22]
4.1 - Abstract [Seite 22]
4.2 - Non-Small Cell Lung Cancer [Seite 23]
4.3 - Staging of Lung Cancer - Distant Metastases [Seite 32]
4.4 - Prediction and Monitoring Response to Therapy [Seite 40]
4.5 - Pleural Metastases [Seite 42]
4.6 - Cost-Effectiveness [Seite 43]
4.7 - Small Cell Lung Cancer [Seite 44]
4.8 - References [Seite 44]
5 - Whole-Body Magnetic Resonance Imaging for Staging of Lung Cancer [Seite 53]
5.1 - Abstract [Seite 53]
5.2 - Technical Aspects of Whole-Body MRI [Seite 54]
5.3 - Staging of Lung Cancer Using Whole-Body MRI [Seite 54]
5.4 - Conclusions [Seite 60]
5.5 - References [Seite 60]
6 - Bronchoscopy/Endobronchial Ultrasound [Seite 62]
6.1 - Abstract [Seite 62]
6.2 - EBUS-TBNA: Technique [Seite 63]
6.3 - Clinical Results [Seite 65]
6.4 - Complications [Seite 67]
6.5 - Conclusion [Seite 67]
6.6 - References [Seite 68]
7 - New Developments in Videomediastinoscopy: Video-Assisted Mediastinoscopic Lymphadenectomy and Mediastinoscopic Ultrasound [Seite 70]
7.1 - Abstract [Seite 70]
7.2 - Methods [Seite 71]
7.3 - Results [Seite 71]
7.4 - Comments [Seite 74]
7.5 - Implications for Clinical Practice and Further Research [Seite 76]
7.6 - References [Seite 77]
8 - Resection in Stage I/II Non-Small Cell Lung Cancer [Seite 78]
8.1 - Abstract [Seite 78]
8.2 - Surgery in Stages I and II [Seite 79]
8.3 - Conclusion [Seite 82]
8.4 - References [Seite 82]
9 - Role of Mediastinal Lymph Node Dissection in Non-Small Cell Lung Cancer [Seite 85]
9.1 - Abstract [Seite 85]
9.2 - Surgical Technique of Systematic Lymph Node Dissection [Seite 86]
9.3 - Role of Nodal Involvement on Survival [Seite 88]
9.4 - Impact of Mediastinal Lymph Node Dissection on Operative Morbidity, Mortality and Quality of Life [Seite 88]
9.5 - Diagnostic Role of Mediastinal Lymph Node Dissection [Seite 89]
9.6 - Therapeutic Role of Mediastinal Lymph Node Dissection [Seite 90]
9.7 - Conclusion [Seite 91]
9.8 - References [Seite 91]
10 - Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer [Seite 94]
10.1 - Abstract [Seite 94]
10.2 - Radiation Therapy alone in Early Non-Small Cell Lung Cancer [Seite 95]
10.3 - Avenues for an Improvement of RT Alone in Early NSCLC [Seite 98]
10.4 - References [Seite 99]
11 - Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer [Seite 101]
11.1 - Abstract [Seite 101]
11.2 - Definitions of Stereotactic Body Radiation Therapy [Seite 102]
11.3 - Staging Procedures before SBRT [Seite 104]
11.4 - Implementation of Techniques in Clinical Routine [Seite 105]
11.5 - Biological Basis of Hypofractionated SBRT [Seite 108]
11.6 - Historical Aspects and Early Clinical Experience in SBRT of Lung Cancer [Seite 109]
11.7 - Clinical Experience [Seite 109]
11.8 - Follow-Up Recommendations [Seite 116]
11.9 - Future [Seite 117]
11.10 - References [Seite 117]
12 - Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer [Seite 122]
12.1 - Abstract [Seite 122]
12.2 - Discussion of Stage-Related Treatment [Seite 123]
12.3 - Conclusions [Seite 127]
12.4 - References [Seite 127]
13 - Stage III: Definitive Chemoradiotherapy [Seite 129]
13.1 - Abstract [Seite 129]
13.2 - Optimization of Combined Radiotherapy and Chemotherapy [Seite 130]
13.3 - Which Chemotherapy and Radiotherapy Regimens Are Optimal for Concurrent Chemoradiotherapy? [Seite 133]
13.4 - How Do Comorbidities Influence the Performance of Concurrent Chemoradiotherapy? [Seite 137]
13.5 - References [Seite 139]
14 - Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer [Seite 142]
14.1 - Abstract [Seite 142]
14.2 - Landmark Studies Concerning Adjuvant Platinum-Based Chemotherapy [Seite 143]
14.3 - Negative Studies [Seite 144]
14.4 - The LACE (Lung Adjuvant Cisplatin Evaluation) Meta-Analysis (table 2) [Seite 144]
14.5 - Adjuvant Chemotherapy and Stage (table 3) [Seite 145]
14.6 - Which Chemotherapy Combination? [Seite 147]
14.7 - Adjuvant Radiotherapy [Seite 147]
14.8 - Patient Selection and Predictive or Prognostic Factors [Seite 147]
14.9 - Neoadjuvant Chemotherapy [Seite 149]
14.10 - Conclusion [Seite 149]
14.11 - References [Seite 150]
15 - Postoperative Irradiation in Non-Small Cell Lung Cancer [Seite 152]
15.1 - Abstract [Seite 152]
15.2 - References [Seite 155]
16 - Altered Fractionation Schemes in Radiotherapy [Seite 157]
16.1 - Abstract [Seite 157]
16.2 - Hypofractionated Stereotactic Body Radiotherapy for NSCLC (Stage I) [Seite 158]
16.3 - Hyperfractionated Accelerated Radiotherapy for Stage III NSCLC [Seite 161]
16.4 - References [Seite 162]
17 - Chemotherapy of Advanced Non-Small Cell Lung Cancer [Seite 164]
17.1 - Abstract [Seite 164]
17.2 - Pemetrexed [Seite 165]
17.3 - Cisplatin- vs. Carboplatin-Based Chemotherapy [Seite 165]
17.4 - Elderly Patients and Patients with Reduced Performance Status [Seite 166]
17.5 - Customized Chemotherapy [Seite 166]
17.6 - Targeted Therapies [Seite 167]
17.7 - Maintenance Therapy [Seite 167]
17.8 - Systemic Chemotherapy in Patients Progressing after First-Line Chemotherapy [Seite 168]
17.9 - Assessment of Efficacy [Seite 168]
17.10 - References [Seite 169]
18 - Radiotherapy [Seite 171]
18.1 - Abstract [Seite 171]
18.2 - Clinical Manifestations of Advanced Lung Carcinoma [Seite 171]
18.3 - Palliative Potential of Radiotherapy [Seite 172]
18.4 - Treatment Strategies [Seite 174]
18.5 - References [Seite 178]
19 - Treatment of Limited Disease Small Cell Lung Cancer [Seite 180]
19.1 - Abstract [Seite 180]
19.2 - Thoracic Radiotherapy [Seite 181]
19.3 - Patient Selection [Seite 184]
19.4 - Future Perspectives [Seite 185]
19.5 - References [Seite 185]
20 - Radiochemotherapy in Extensive Disease Small Cell Lung Cancer ED-SCLC [Seite 187]
20.1 - Abstract [Seite 187]
20.2 - RT in ED-SCLC Trial [Seite 188]
20.3 - Future Approaches [Seite 191]
20.4 - Conclusions [Seite 192]
20.5 - References [Seite 192]
21 - Radiotherapy for Extensive Stage Small Cell Lung Cancer [Seite 194]
21.1 - Abstract [Seite 194]
21.2 - Introduction [Seite 194]
21.3 - Brain Metastases [Seite 195]
21.4 - Prophylactic Cranial Irradiation [Seite 195]
21.5 - Thoracic Radiotherapy [Seite 197]
21.6 - References [Seite 198]
22 - Controversies in the Treatment of Advanced Stages of Small Cell Lung Cancer [Seite 200]
22.1 - Abstract [Seite 200]
22.2 - First-Line Chemotherapy [Seite 200]
22.3 - Prophylactic Cranial Irradiation after First-Line Chemotherapy [Seite 202]
22.4 - Second-Line Chemotherapy [Seite 202]
22.5 - References [Seite 203]
23 - Complementary and Alternative Medicinein Lung Cancer Patients: A Neglected Phenomenon? [Seite 205]
23.1 - Abstract [Seite 205]
23.2 - Methods [Seite 207]
23.3 - Results [Seite 208]
23.4 - Discussion [Seite 209]
23.5 - Conclusions [Seite 210]
23.6 - References [Seite 211]
24 - Author Index [Seite 213]
25 - Subject Index [Seite 214]
26 - Back cover [Seite 219]